Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MST-0312 |
| Synonyms | |
| Therapy Description |
MST-0312 is a bispecific antibody targeting FAP and LTBR, which activates LTBR signaling and potentially induces antitumor immune activity (Cancer Res (2026) 86 (8_Supplement): LB257). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MST-0312 | MST0312|MST 0312 | MST-0312 is a bispecific antibody targeting FAP and LTBR, which activates LTBR signaling and potentially induces antitumor immune activity (Cancer Res (2026) 86 (8_Supplement): LB257). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07610941 | Phase I | MST-0312 MST-0312 + Pembrolizumab | Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies (STARLYS) | Recruiting | ESP | 0 |